Weekly Cisplatin during cranial irradiation for malignant melanoma metastatic to brain

David J. Stewart, Lynn G Feun, Moshe Maor, Milam Leavens, M. Andrew Burgess, Robert S. Benjamin, Gerald P. Bodey

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Because Cisplatin potentiates the effect of radiotherapy in animal tumor systems and because Cisplatin is capable of causing regressions of human malignant melanomas, a study was initiated in patients with malignant melanoma metastatic to brain to investigate the feasibility of administering Cisplatin once a week during cranial irradiation. Cisplatin 40 mg/m2/week (three doses) was given LV. to 18 patients during whole brain irradiation, 3 000 rads in 12 fractions over 2 1/2 weeks. Eleven patients also received Cisplatin 120 mg/m2 every three weeks, starting three weeks after cranial irradiation. Median survival was ten weeks, and only one of 13 patients whose brain metastases had not been resected experienced neurological and CT scan improvement. Thirteen patients have died, and brain metastases were a major cause. No regression of extracerebral tumor was seen in 15 patients with eveluable extracerebral lesions. During weekly low-dose Cisplatin administration, nausea and vomiting were moderate to severe. No granulocytopenia was noted, although three courses were associated with mild thrombocytopenia. Mucositis, peri orbital swelling, vertigo, and headache were each noted in two of 51 courses of treatment and seizures, ototoxicity, pancreatitis, and hiccups were each noted in one course. Renal toxicity and ototoxicity each developed in three of the 11 patients receiving Cisplatin 120 mg/ m2, and nausea and vomiting were severe.

Original languageEnglish
Pages (from-to)49-51
Number of pages3
JournalJournal of Neuro-Oncology
Volume1
Issue number1
DOIs
StatePublished - Mar 1 1983
Externally publishedYes

Fingerprint

Cranial Irradiation
Cisplatin
Melanoma
Brain
Nausea
Vomiting
Hiccup
Neoplasm Metastasis
Mucositis
Agranulocytosis
Vertigo
Thrombocytopenia
Pancreatitis
Headache
Neoplasms
Seizures
Radiotherapy
Kidney
Survival

Keywords

  • Cisplatin
  • intracerebral
  • melanoma
  • radiopotentiation

ASJC Scopus subject areas

  • Neuroscience(all)
  • Oncology
  • Clinical Neurology
  • Cancer Research

Cite this

Stewart, D. J., Feun, L. G., Maor, M., Leavens, M., Burgess, M. A., Benjamin, R. S., & Bodey, G. P. (1983). Weekly Cisplatin during cranial irradiation for malignant melanoma metastatic to brain. Journal of Neuro-Oncology, 1(1), 49-51. https://doi.org/10.1007/BF00153641

Weekly Cisplatin during cranial irradiation for malignant melanoma metastatic to brain. / Stewart, David J.; Feun, Lynn G; Maor, Moshe; Leavens, Milam; Burgess, M. Andrew; Benjamin, Robert S.; Bodey, Gerald P.

In: Journal of Neuro-Oncology, Vol. 1, No. 1, 01.03.1983, p. 49-51.

Research output: Contribution to journalArticle

Stewart, DJ, Feun, LG, Maor, M, Leavens, M, Burgess, MA, Benjamin, RS & Bodey, GP 1983, 'Weekly Cisplatin during cranial irradiation for malignant melanoma metastatic to brain', Journal of Neuro-Oncology, vol. 1, no. 1, pp. 49-51. https://doi.org/10.1007/BF00153641
Stewart, David J. ; Feun, Lynn G ; Maor, Moshe ; Leavens, Milam ; Burgess, M. Andrew ; Benjamin, Robert S. ; Bodey, Gerald P. / Weekly Cisplatin during cranial irradiation for malignant melanoma metastatic to brain. In: Journal of Neuro-Oncology. 1983 ; Vol. 1, No. 1. pp. 49-51.
@article{de496652ca7e44c79725fe6dc54b73bd,
title = "Weekly Cisplatin during cranial irradiation for malignant melanoma metastatic to brain",
abstract = "Because Cisplatin potentiates the effect of radiotherapy in animal tumor systems and because Cisplatin is capable of causing regressions of human malignant melanomas, a study was initiated in patients with malignant melanoma metastatic to brain to investigate the feasibility of administering Cisplatin once a week during cranial irradiation. Cisplatin 40 mg/m2/week (three doses) was given LV. to 18 patients during whole brain irradiation, 3 000 rads in 12 fractions over 2 1/2 weeks. Eleven patients also received Cisplatin 120 mg/m2 every three weeks, starting three weeks after cranial irradiation. Median survival was ten weeks, and only one of 13 patients whose brain metastases had not been resected experienced neurological and CT scan improvement. Thirteen patients have died, and brain metastases were a major cause. No regression of extracerebral tumor was seen in 15 patients with eveluable extracerebral lesions. During weekly low-dose Cisplatin administration, nausea and vomiting were moderate to severe. No granulocytopenia was noted, although three courses were associated with mild thrombocytopenia. Mucositis, peri orbital swelling, vertigo, and headache were each noted in two of 51 courses of treatment and seizures, ototoxicity, pancreatitis, and hiccups were each noted in one course. Renal toxicity and ototoxicity each developed in three of the 11 patients receiving Cisplatin 120 mg/ m2, and nausea and vomiting were severe.",
keywords = "Cisplatin, intracerebral, melanoma, radiopotentiation",
author = "Stewart, {David J.} and Feun, {Lynn G} and Moshe Maor and Milam Leavens and Burgess, {M. Andrew} and Benjamin, {Robert S.} and Bodey, {Gerald P.}",
year = "1983",
month = "3",
day = "1",
doi = "10.1007/BF00153641",
language = "English",
volume = "1",
pages = "49--51",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - Weekly Cisplatin during cranial irradiation for malignant melanoma metastatic to brain

AU - Stewart, David J.

AU - Feun, Lynn G

AU - Maor, Moshe

AU - Leavens, Milam

AU - Burgess, M. Andrew

AU - Benjamin, Robert S.

AU - Bodey, Gerald P.

PY - 1983/3/1

Y1 - 1983/3/1

N2 - Because Cisplatin potentiates the effect of radiotherapy in animal tumor systems and because Cisplatin is capable of causing regressions of human malignant melanomas, a study was initiated in patients with malignant melanoma metastatic to brain to investigate the feasibility of administering Cisplatin once a week during cranial irradiation. Cisplatin 40 mg/m2/week (three doses) was given LV. to 18 patients during whole brain irradiation, 3 000 rads in 12 fractions over 2 1/2 weeks. Eleven patients also received Cisplatin 120 mg/m2 every three weeks, starting three weeks after cranial irradiation. Median survival was ten weeks, and only one of 13 patients whose brain metastases had not been resected experienced neurological and CT scan improvement. Thirteen patients have died, and brain metastases were a major cause. No regression of extracerebral tumor was seen in 15 patients with eveluable extracerebral lesions. During weekly low-dose Cisplatin administration, nausea and vomiting were moderate to severe. No granulocytopenia was noted, although three courses were associated with mild thrombocytopenia. Mucositis, peri orbital swelling, vertigo, and headache were each noted in two of 51 courses of treatment and seizures, ototoxicity, pancreatitis, and hiccups were each noted in one course. Renal toxicity and ototoxicity each developed in three of the 11 patients receiving Cisplatin 120 mg/ m2, and nausea and vomiting were severe.

AB - Because Cisplatin potentiates the effect of radiotherapy in animal tumor systems and because Cisplatin is capable of causing regressions of human malignant melanomas, a study was initiated in patients with malignant melanoma metastatic to brain to investigate the feasibility of administering Cisplatin once a week during cranial irradiation. Cisplatin 40 mg/m2/week (three doses) was given LV. to 18 patients during whole brain irradiation, 3 000 rads in 12 fractions over 2 1/2 weeks. Eleven patients also received Cisplatin 120 mg/m2 every three weeks, starting three weeks after cranial irradiation. Median survival was ten weeks, and only one of 13 patients whose brain metastases had not been resected experienced neurological and CT scan improvement. Thirteen patients have died, and brain metastases were a major cause. No regression of extracerebral tumor was seen in 15 patients with eveluable extracerebral lesions. During weekly low-dose Cisplatin administration, nausea and vomiting were moderate to severe. No granulocytopenia was noted, although three courses were associated with mild thrombocytopenia. Mucositis, peri orbital swelling, vertigo, and headache were each noted in two of 51 courses of treatment and seizures, ototoxicity, pancreatitis, and hiccups were each noted in one course. Renal toxicity and ototoxicity each developed in three of the 11 patients receiving Cisplatin 120 mg/ m2, and nausea and vomiting were severe.

KW - Cisplatin

KW - intracerebral

KW - melanoma

KW - radiopotentiation

UR - http://www.scopus.com/inward/record.url?scp=0020961283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020961283&partnerID=8YFLogxK

U2 - 10.1007/BF00153641

DO - 10.1007/BF00153641

M3 - Article

C2 - 6687194

AN - SCOPUS:0020961283

VL - 1

SP - 49

EP - 51

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 1

ER -